FDA Approved: ROZLYTREK — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Rozlytrek (entrectinib) submitted by Genentech, expanding its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ntrk Gene Fusion-positive Solid Tumors
• Ros1-positive Non-small Cell Lung Cancer

Drugs mentioned

• Rozlytrek (entrectinib)

Snippet

SUPPL AP for ROZLYTREK (ENTRECTINIB)